Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.94% | 3.87% | -24.77% | -15.78% | -9.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -57.18% | 7.78% | 20.64% | 39.30% | 117.04% |
| Operating Income | 57.18% | -7.78% | -20.64% | -39.30% | -117.04% |
| Income Before Tax | 38.81% | -12.68% | -48.18% | -227.19% | -123.21% |
| Income Tax Expenses | 0.00% | -- | -- | -- | -58.02% |
| Earnings from Continuing Operations | 38.80% | -12.66% | -48.18% | -227.19% | -123.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.80% | -12.66% | -48.18% | -227.19% | -123.02% |
| EBIT | 57.18% | -7.78% | -20.64% | -39.30% | -117.04% |
| EBITDA | 57.61% | -7.94% | -20.90% | -38.38% | -115.58% |
| EPS Basic | 38.85% | -12.58% | -49.28% | -220.19% | -117.45% |
| Normalized Basic EPS | 56.50% | -12.60% | -27.34% | -47.48% | -118.74% |
| EPS Diluted | 38.85% | -14.28% | -49.28% | -220.19% | -117.45% |
| Normalized Diluted EPS | 56.50% | -12.60% | -27.34% | -47.48% | -118.74% |
| Average Basic Shares Outstanding | 0.09% | 0.07% | -0.74% | 2.18% | 2.56% |
| Average Diluted Shares Outstanding | 0.09% | 0.07% | -0.74% | 2.18% | 2.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |